Inhibitory effect of acetylshikonin on human gastric carcinoma cell line SGC-7901 in vitro and in vivo

Figure 1 Effect of acetylshikonin on proliferation of SGC-7901 cells in vitro. SGC-7901 cells were treated with various concentrations of acetylshikonin for 48 h. Tumor growth inhibitory rate was determined by MTT assay.

Figure 2 Effect of acetylshikonin on expression of Bcl-2 and Bax in SGC-7901 cells. Lower panel: Ratios of protein quantitation of Bcl-2 or Bax to actin. Each experiment was independently performed three times. ^aP < 0.05, ^bP < 0.01 vs control group.

Figure 3 Effect of acetylshikonin on Bcl-2 and Bax mRNA expression levels in SGC-7901 cells. Lower panel: Ratios of mRNA quantitation of Bcl-2 or Bax to actin. Each experiment was independently performed three times. ^aP < 0.05, ^bP < 0.01 vs control group.

Figure 4 Anti-tumor effects of acetylshikonin in vivo. Representative tumors from each group were shown. Lower panel: Average tumor weight of sacrificed animals. ^aP < 0.05, ^bP < 0.01 vs control group.

Figure 5 Effect of acetylshikonin on expression of Bax, Bcl-2 and Caspase 3 in SGC-7901 tumor tissues. Tumor tissue sections showed strong Bax/Caspase 3 cytoplasmic staining and weak Bcl-2 cytoplasmic staining of tumor cells in acetylshikon treatment groups, as well as the integrated optical density (IOD) for the expression of Bax, Bcl-2 and Caspase 3 in SGC-7901 cells. ^aP < 0.05, ^bP < 0.01 vs control group.